Earnings Summary

Relay Therapeutics Inc’s revenue fell -48.35% since last year same period to $0.34Mn in the Q3 2022. On a quarterly growth basis, Relay Therapeutics Inc has generated -5.75% fall in its revenue since last 3-months.

Relay Therapeutics Inc’s net profit fell -38.37% since last year same period to $-84.17Mn in the Q3 2022. On a quarterly growth basis, Relay Therapeutics Inc has generated -9.62% fall in its net profits since last 3-months.

Relay Therapeutics Inc’s net profit margin fell -167.88% since last year same period to -24468.6% in the Q3 2022. On a quarterly growth basis, Relay Therapeutics Inc has generated -16.31% fall in its net profit margins since last 3-months.

Relay Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a 1.41% jump from last quarter’s estimates.

Relay Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.7.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Relay Therapeutics Inc’s return on assets (ROA) stands at -0.18.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Relay Therapeutics Inc’s return on equity (ROE) stands at -0.31.